AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02641990
Drug: ITCA placebo, ITCA 650 20/60 mcg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITCA osmotic mini pump delivering placebo and Levora® for 28 days, followed by Levora® and ITCA 650 osmotic mini pump delivering exenatide 20/60 mcg/day and Levora® for 28 days
Trial: NCT03375034
Drug: NDMC 20mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of one NDMC 20mg capsule and two Placebo capsules
Trial: NCT03375034
Drug: NDMC60mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of three NDMC 20mg capsules
Trial: NCT03375034
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of three Placebo capsules
Trial: NCT01039688
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets administered at a dose of 5 mg BID for 24 months
Trial: NCT00668863
Drug: FOLFIRI (The combination regimen of Irinotecan, l-Leucovorin and 5-Fluorouracil)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRI treatment with Sunitinib on Day, Irinotecan 180M/M IV , l-Leucovorin 200M/M, 5FU 400M/M bolus and 2400M/M in 46-hour continuous infusion on Day1 each 42 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
Trial: NCT01065220
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 microgram TTS twice a week
Trial: NCT01065220
Drug: 5-alpha reductase inhibitor
RxNorm normalized name: 5-alpha reductase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1mg daily
Trial: NCT03301025
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: given a placebo identical capsule once one hour before anesthesia
Trial: NCT04102462
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules
Trial: NCT00482378
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 4 mg by IV monthly.
Trial: NCT03546556
Drug: Fluorothymidine (FLT)
RxNorm normalized name: FLUOROTHYMIDINE F-18
DrugBank: Alovudine F-18 (DB14930)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A total of 12 patients who have undergone allogenic bone marrow transplantation will undergo FLT-PET-MRI imaging on two separate occasions. In addition to the 12 allogenic transplant patients, 3 patients undergoing autologous stem cell transplant will also be imaged the same two time points in order to determine how much of the FLT signal observed after allogeneic transplant is unique to that population and the result of allo-antigen driven T cell expansion.
Trial: NCT01486966
Drug: insulin NPH
RxNorm normalized name: insulin NPH human isophane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) once daily using NovoPen®4
Trial: NCT01486966
Drug: human soluble insulin
RxNorm normalized name: Recombinant human soluble insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) three times a day before a meal using NovoPen®4
Trial: NCT03517735
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The dosage is modified automatically by the device or according to the new medical prescription.
Trial: NCT00361881
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose 5 times daily for 5 days
Trial: NCT00569140
Drug: E10030
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection
Trial: NCT00880620
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01673828
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intravenous solution, 0.9% sodium chloride injection with 6% sulfobutyl ether β-cyclodextrin sodium
Trial: NCT00879385
Drug: Dacogen™ (decitabine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dacogen™ (decitabine) is a FDA approved drug (NDA - 021790) for the treatment of myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia).~Decitabine will be given on this study at 45 mg/m2 IV over 2 hrs
Trial: NCT00879385
Drug: Vectibix® (panitumumab)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vectibix® (panitumumab) is a FDA approved drug (BLA-125147) indicated as a single agent for the treatment of EGFR-expressing metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine, oxaliplatin, and irinotecan chemotherapy regimens. Approval is based on progression-free survival; no data demonstrate an improvement in disease-related symptoms or increased survival.~DRUG DESCRIPTION Vectibix® (panitumumab) is a recombinant, human IgG2 kappa monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). Panitumumab has an approximate molecular weight of 147 kDa. Panitumumab is produced in genetically engineered mammalian (Chinese Hamster Ovary) cells.~Panitumumab will be given on this study at 6 mg/kg, IV over 1 hr
Trial: NCT00967317
Drug: Otosynalar®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drip 3 drops in the ear 2 times a day. The medication should be used by more than 3 days after which the patient must return to the doctor.
Trial: NCT00043043
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02365805
Drug: Epirubicin + Ciclofosfamide + Fluorouracil + Paclitaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin 90 mg/m2 + Ciclofosfamide 600 mg/m2 + 5-Fluorouracil 600 mg/m2 intravenous infusion on day 1 every three weeks, for four cycles; followed by Paclitaxel 100 mg/m2 weekly for eight weeks.
Trial: NCT02365805
Drug: Epirubicin + Cisplatin + Fluorouracil
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epirubicin 60 mg/m2 + Cisplatin 60 mg/m2 intravenous infusion on day 1 every three weeks and 5-Fluorouracil 200 mg/m2/day for eight cycles.
Trial: NCT00728195
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo capsules orally for 12 weeks.
Trial: NCT01372761
Drug: ZGN-433
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive placebo or ZGN-433 twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.
Trial: NCT03073369
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Placebo - one capsule once daily for 6 weeks
Trial: NCT01667302
Drug: Radiotherapy followed by chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy Technique: IMRT Total dose: 50 Gy Per fraction: 2 Gy Chemotherapy: q3w Dexamethasone 40 mg d1-4 Ifosfamide 1200mg/m2 d1-4 Etoposide 60 mg/m2 d1-4 Cisplatin 20mg/m2 d1-4 Peg-asparaginase 2000 IU/m2 d1
Trial: NCT02547922
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration every 4 week from Week 0 to Week 100 in addition to SOC which will continue until Week 112
Trial: NCT03332459
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants who received placebo in a feeding Phase 2 study (64041575RSV2004) will be observed in this study.
Trial: NCT02111707
Drug: Rectal indomethacin 100mg one time before or after ERCP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive rectal indomethacin suppository 30 minutes before or immediately after ERCP for prevention of post-procedure pancreatitis. Patients will be randomized to the timing of administration.
Trial: NCT00332046
Drug: GW679769
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02354235
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04614636
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lympho-conditioning Agent
Trial: NCT02280096
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo arm will include Microcrystalline Cellulose placebo
Trial: NCT04802928
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03549221
Drug: 0.6 mg 1:1000 epinephrine (0.6 ml)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In group 1, the multimodal anesthetic cocktail consisted of 100 mg Levobupivacaine (0.5%, 20 mL) 30 mg ketorolac (1 ml) and 0.6 mg 1:1000 epinephrine (0.6 ml). In group 2, the multimodal anesthetic cocktail consisted of 100 mg Levobupivacaine (0.5%, 20 mL) and 30 mg ketorolac (1 ml). Both groups were mixed with a 0.9% normal saline solution to a total volume of 100 ml.
Trial: NCT02630394
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04343391
Drug: Pharmacological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual in PC
Trial: NCT02919761
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo 1 mL for subcutaneous injection
Trial: NCT02967640
Drug: NaCl 9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2,5 ml - if well tolerated immediately followed by another 2,5 ml - of a 9% NaCl solution injected 2 times with 1-12 weeks between each injection
Trial: NCT01037140
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral placebo tablets similar to active comparator
Trial: NCT02282085
Drug: Oral Antipsychotic (i.e. aripiprazole, risperidone, lurasidone, quetiapine, olanzapine, ziprasidone, etc)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antipsychotic medication
Trial: NCT02865928
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same injection technique as intervention arm with normal saline
Trial: NCT01311882
Drug: MK-4305 40 mg
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 x 10 mg MK-4305 tablets
Trial: NCT02063425
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 pill of 20mg / day, during 3 months
Trial: NCT02063425
Drug: Placebo of fluoxetine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 pill of 20mg/day, during 3 months
Trial: NCT00855686
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral dose
Trial: NCT01311882
Drug: MK-4305 20 mg
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 10 mg MK-4305 tablets
Trial: NCT01311882
Drug: Matching Placebo for MK-4305
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo for MK-4305
Trial: NCT00430105
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00587717
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two 80 mg pills simvastatin taken 24 hours prior to surgery
Trial: NCT00587717
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: take 2 80 mg pills placebo 24 hours prior to surgery
Trial: NCT06125366
Drug: BAY1747846
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose; IV injection.
Trial: NCT06125366
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose; IV injection.
Trial: NCT01848665
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01848665
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02102295
Drug: Experimental toothpaste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental toothpaste was containing 0.3% L-ascorbic acid 2-phosphate magnesium salt and 950 ppm fluoride. The registered participants were instructed to brush their teeth twice a day in their customary manner.
Trial: NCT04456634
Drug: 20 mg/120 mg artemether-lumefantrine (AL) + 20 mg ruxolitinib phosphate (Rux)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rux administered 2 hours after AL administration, twice daily (b.i.d) for 3 consecutive days (6 doses in total).
Trial: NCT00515151
Drug: 74% Ethanol with 10% 2-propanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Before insertion of the catheter, the entry site was disinfected with the assigned solution over an area of \>200 cm² for at least one minute. The assigned solution was then applied for care of the entry site during the change of dressings, usually every 2 to 3 days.
Trial: NCT03198728
Drug: SOV2012-F1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral preparation of testosterone undecanoate (TU)
Trial: NCT01045967
Drug: Prevacid®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg delayed-release Capsule
Trial: NCT02993588
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin 6 mg tablet once daily
Trial: NCT02719210
Drug: Hypertonic 3% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03481894
Drug: Kabiven®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion should start at a low dose (i.e., 12.5 to 25 mL/kg, corresponding to 10.6 to 21.2 kcal/kg/day, 0.49 to 0.98 g lipids/kg/day, 0.41 to 0.83 g amino acids/kg/day and 1.2 to 2.4 g dextrose/kg/day) followed by stepwise increase to the individual target for PN calories.~The daily dose of the study PN should be infused at a constant rate over 20 to 24 hours.~Route of Administration: Infusion into a central vein. Duration of Treatment: Study treatment will last for a minimum of 5 and a maximum of 8 consecutive days. Study treatment will be stopped if oral and/or enteral intake covers 80% or more of caloric requirements. If the indication for PN continues after 8 study days, PN will continue per normal institution policy.
Trial: NCT03481894
Drug: Compounded standard parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion should start at a low dose (i.e., 12.5 to 25 mL/kg, corresponding to 10.6 to 21.2 kcal/kg/day, 0.49 to 0.98 g lipids/kg/day, 0.41 to 0.83 g amino acids/kg/day and 1.2 to 2.4 g dextrose/kg/day) followed by stepwise increase to the individual target for PN calories.~The daily dose of the study PN should be infused at a constant rate over 20 to 24 hours.~Route of Administration: Infusion into a central vein. Duration of Treatment: Study treatment will last for a minimum of 5 and a maximum of 8 consecutive days. Study treatment will be stopped if oral and/or enteral intake covers 80% or more of caloric requirements. If the indication for PN continues after 8 study days, PN will continue per normal institution policy.
Trial: NCT00043719
Drug: Calcium supplement with vitamin D
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01911611
Drug: RO6870868
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single ascending doses
Trial: NCT01911611
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single ascending doses
Trial: NCT04507022
Drug: Aromatase inhibitor
RxNorm normalized name: Aromatase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg twice daily for 5 days
Trial: NCT02372578
Drug: ASP3662
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02372578
Drug: ASP3662 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00959946
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Doses in part 1 include capecitabine 750 mg/m2 BID on days 1-14; capecitabine 625 mg/m2 BID on days 1-14. Depending on safety, capecitabine can also be administered at 1000 mg/m2 BID. The MTD of the combination treatment determined from part 1, will be administered in part 2 (phase 2).
Trial: NCT01202955
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day 1 100mg three times per day Day 2 - Day 7 200mg three times per day Day 8 200mg twice a day Day 9 200mg once a day Day 10 100mg once a day
Trial: NCT01304342
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 microgram/kg/h, continuous infusion, 5 min before and during the ERCP
Trial: NCT01304342
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal fentanyl 200 micrograms 5 min before the ERCP
Trial: NCT01304342
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline intravenously and intranasally
Trial: NCT03009136
Drug: SCRT
RxNorm normalized name: ExoSCRT Derma Signal Kit SRLV KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: composed of eight herbs: Glycyrrhiza uralensis Fischer 1g Zingiber officinale Roscoe 0.5g Cinnamomum cassia Blume 0.2g, Ephedra sinica Stapf 0.5g, Pinellia ternata Breitenbach 2.67g, Paeonia lactiflora PALL 1g, Asiasarum sieboldi F. Maekawa 0.5g, Schisandra chinensis 2.67g (per 9g of granules)
Trial: NCT03009136
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: is made of lactose, corn starch and caramel coloring, and has appearance, shape, weight, taste, and color similar to SCRT
Trial: NCT03982303
Drug: Hemay102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemay102 was administered through i.v. infusion for 4hrs.
Trial: NCT01818713
Drug: 2B3-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/m2 2B3-101 intravenous 3-weekly administration
Trial: NCT01755338
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04396730
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered daily along with oral contraceptives daily for 24 days.
Trial: NCT04025359
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02947334
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01924195
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo QD po.
Trial: NCT02340572
Drug: PRS-080#022-DP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hepcidin antagonist
Trial: NCT01638611
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Equal volumes of placebo will be given by subcutaneous injection in the abdomen to 2 randomized subjects per dosing cohort.
Trial: NCT02340572
Drug: PRS-080-Placebo#001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment
Trial: NCT02233582
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: We are simply testing if taking ibuprofen upon ascent to altitude is associated with a delayed acclimatization response to the high altitude hypoxia.
Trial: NCT00903994
Drug: Ketoprofen Topical Patch 20%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen is a pressure-sensitive adhesive material containing 20% Ketoprofen which is applied to a polyester textile and covered with a foil release liner.for the treatment of mild to moderate acute pain associated with Tendonitis or Bursitis of the shoulder, elbow or knee
Trial: NCT02092168
Drug: BIA 9-1067
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01503892
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo- one tablet twice daily for twelve months.
Trial: NCT00381173
Drug: Cyclophosphamide & ZYC300 (ZYC300 with cyclophosphamide pre-dosing)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who meet all entry criteria will be administered 600 mg/m\^2 cyclophosphamide intravenously 3 days before each dose of ZYC300. ZYC300 will be administered at 400 micrograms DNA/total dose every two weeks for a maximum of six doses (6 cycles).
Trial: NCT02187224
Drug: Placebo (for Progesterone)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02756546
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02083575
Drug: Vitamin C, Defriprone, deferisarox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: adjuvant vitamin c with iron chelator.
Trial: NCT00092027
Drug: Comparator: placebo / Duration of Treatment: 6 months
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03848234
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 trans dermal patches to be changed twice a week for the duration of 8 weeks.
Trial: NCT02756546
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00072007
Drug: CHOP regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHOP regimen
Trial: NCT00072007
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cyclophosphamide
Trial: NCT00072007
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: doxorubicin hydrochloride
Trial: NCT01599975
Drug: Matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets of matched placebo daily by mouth